Life sciences | Claude by Anthropic (original) (raw)
Claude works through problems alongside your team and shows its work, from your first hypothesis to the final submission.
"At AstraZeneca, AI is a defining force reshaping how we operate across R&D end-to-end. Through R&D powered by AI, we can derive deeper biological insights that help us push the boundaries of science to deliver life-changing medicines, including novel approaches for patient selection. Claude's commitment to mechanistic interpretability provides a safe, secure, and steerable model to empower our science-first approach."
Dr. Jorge Reis Filho, Chief of AI for Science Innovation, AstraZeneca R&D
"By reducing manual burden and enabling greater scale across our operations, our partnership with Anthropic will empower our teams to focus more time on high-value scientific and strategic work, with the goal of accelerating our path to patient impact."
Tahamtan Ahmadi, M.D., Ph.D, Executive Vice President and Chief Medical Officer, Genmab
"Veeva AI is industry-specific agentic AI that leverages Veeva's deep applications, data, domain expertise, and Anthropic's Claude. This unique combination allows us to bring the transformative promise of AI to life sciences at scale."
Andy Han, Senior Vice President, Veeva AI
“Opus 4.5 is an incredible model and a great choice for computational biology. The model is excellent at coding, reasoning about biology, and understanding scientific figures.”
Andrew White, CTO, Edison Scientific
"Commercial pharma teams are entering an era where real-time clinical intelligence and AI agents fundamentally change how therapies reach the right patients at the right time. Anthropic's models are unmatched in their reasoning capabilities and safety design. This collaboration accelerates our shared mission to ensure that clinical-grade agentic AI becomes a trusted, transformative force across global pharma."
Chris Mansi, MD, CEO and co-founder of Viz.ai
“Broad Institute scientists pursue the most ambitious questions in biology and medicine, and we create and share tools to help empower scientists everywhere. We’ve been working closely with Manifold on the next generation of the Terra.bio platform—Terra Powered by Manifold. Among the most exciting of these upgrades are AI agents built on Claude that enable scientists to carry out tasks at an entirely new scale and efficiency and explore scientific domains in previously impossible ways.”
Heather Jankins, Head of Data Science Platform
“Accessing 10x’s single cell and spatial analysis capabilities has traditionally required computational expertise - from writing command-line scripts to managing high-performance computing systems. Now, these same tools can respond to questions asked in plain English. Using Claude, researchers can now perform common analytical tasks—including aligning reads, generating Feature Barcode matrices, performing clustering and other secondary analysis—through a conversational interface that complements traditional computational workflows, making it faster and easier for researchers to engage directly with their data. Claude lowers the barrier to entry for new users and scales to meet the needs of large-scale analyses for advanced research teams.”
Serge Saxonov, Co-founder and CEO
“AI in R&D only works through an ecosystem. Anthropic is doing this right, bringing together the best technologies while putting access, governance, and interoperability first. Benchling is uniquely positioned to contribute. For more than a decade, scientists have trusted us as the source of truth for experimental data and to modernize their workflows. Now we're building AI that powers this next chapter of R&D.”
Ashu Singhal, Co-founder and President
“Claude, paired with internal knowledge libraries, has become integral to Sanofi’s AI-driven transformation and is used by the majority of Sanofians on a daily basis within our internal Concierge app. We are seeing significant efficiency gains across the value-chain by optimizing our processes, while our enterprise-wide deployment has enhanced how our teams work. This collaboration with Anthropic augments human expertise to deliver life-changing medicines faster and more effectively to patients worldwide.”
Emmanuel Frenehard, Chief Digital Officer
“We’ve consistently been one of the first movers when it comes to document and content automation in pharma development. Our work with Anthropic and Claude has set a new standard—we’re not just automating tasks, we’re transforming how medicines get from discovery to the patients who need them.”
Louise Lind Skov, Director Content Digitalisation
“Claude Code has become a powerful accelerator for us at Schrödinger. For the projects where it fits best, Claude Code allows us to turn ideas into working code in minutes instead of hours, enabling us to move up to 10x faster in some cases. As we continue to work with Claude, we are excited to see how we can further transform the way we build and customize our software.”
Pat Lorton, Executive Vice President, Chief Technology Officer, and Chief Operating Officer
“At Manifold, our mission is to power faster, leaner life sciences. Building with Claude has enabled us to develop AI agents that translate questions in the semantic space of scientists to execution in the technical space of specialized datasets and tools. Together, we’re transforming how life sciences R&D will happen in the years ahead.”
Sourav Dey, PhD, Co-founder and Chief AI Officer
“At PwC, we believe responsible AI isn’t just a technology opportunity—it’s a trust imperative. We’re proud to pair our deep sector insight with Claude’s agentic intelligence to reimagine how clinical, regulatory, and commercial teams operate. Together, we’re not just streamlining processes—we’re elevating quality, accelerating discovery, and building systems where confidence scales alongside innovation.”
Matt Wood, US and Global Commercial Technology and Innovation Officer
“When we set out to create an AI agent that could automate bioinformatics analyses, we focused on three key factors to decide what model provider to use: top-ranking at software development, aligned with life sciences, and support for startups. We evaluated half a dozen platforms, and it became clear that Claude was the standout leader. We’re excited to continue this collaboration and bring cutting-edge AI Agents into the world of biotech research.”
Alfredo Andere, Co-founder and CEO
“Claude has been an invaluable progress multiplier for Axiom as we build AI to predict drug toxicity. We’ve used billions of tokens in Claude Code, and use it to write many of our PRs. More recently, Claude agents with MCP servers have become core tools for our scientific work. With the right MCPs, Claude agents can directly query databases and storage services to interpret, transform, and test correlations in data, and help us identify what data and features are most useful for predicting clinical drug toxicity.”
“At EvolutionaryScale, we’re building next-generation AI systems to model the living world. Anthropic’s frontier models accelerate our ability to reason about complex biological data and translate it into scientific insight, helping us push the boundaries of what’s possible in life science discovery.”
Sal Candido, Co-founder, Chief Technology Officer
Claude shows the lowest hallucination rates and is built with biosafety guardrails. When you connect to PubMed, bioRxiv, and research databases, claims are traced to their source, so teams can verify before they act.
Analyze genomic data, synthesize hundreds of papers, and design experiments. With Opus 4.7, Claude shows notable improvements in biology benchmarks including BioPipelineBench, single-cell RNA analysis, and structural biology.
Claude can connect to Benchling, PubMed, 10x Genomics, and ClinicalTrials.gov, so every scientist can connect to data for accurate work.
Novo Nordisk accelerates clinical documentation and drug development with Claude
Claude performs at expert level on real bioinformatics problems, sometimes solving them in unexpected ways.
Advancing life sciences with Claude Opus 4.8
Opus 4.8 brings broader, more reliable reasoning to chemistry, structural biology, bioinformatics pipelines, and lab protocol design – steady, measurable progress on the work researchers do every day.
Bioinformatics analysis
Process genomic data with validated bioinformatics pipelines through Claude Code. Claude connects to 10x Genomics and Benchling, then delivers annotated, reproducible reports you can share with cross-functional teams without needing to provide complex code.
Research synthesis
Survey hundreds of papers in hours instead of weeks. Claude synthesizes findings across PubMed, bioRxiv, and proprietary databases, identifies contradictions, and generates testable hypotheses with verifiable citations tailored to your research questions.
Phase 2 Clinical Trial Protocol
ABX-7291 for Treatment of Parkinson's Disease | DRAFT v0.1
Study Synopsis
Protocol Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABX-7291 in Patients with Early-Stage Parkinson's Disease
Sponsor: [Sponsor Name]
Phase: Phase 2
Indication: Early-stage Parkinson's Disease (Hoehn & Yahr Stage 1-2)
Study Duration: 24 weeks treatment + 4 weeks follow-up
Objectives and Endpoints
Primary Objective
Evaluate the efficacy of ABX-7291 compared to placebo in reducing motor symptoms in patients with early-stage Parkinson's disease.
Primary Endpoint
Change from baseline in MDS-UPDRS Part III (Motor Examination) score at Week 24.
Secondary Endpoints
- Change from baseline in MDS-UPDRS Total Score at Week 24
- Proportion of patients achieving ≥30% improvement in MDS-UPDRS Part III
- Change in PDQ-39 (Quality of Life) score at Week 24
- Safety and tolerability (AEs, laboratory parameters, vital signs)
Study Design
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study. Eligible patients will be randomized 1:1:1 to receive ABX-7291 low dose, ABX-7291 high dose, or placebo for 24 weeks.
Sample Size and Rationale
Total Enrollment: 120 patients (40 per arm)
Statistical Power: 80% power at α=0.05 (two-sided)
Expected Effect Size: 5-point difference in MDS-UPDRS Part III (SD=8)
Dropout Assumption: 15% (based on comparable Phase 2 PD trials)
Rationale: Sample size derived from analysis of 12 comparable Phase 2 trials on ClinicalTrials.gov with similar indications and endpoints.
Regulatory References
- 21 CFR 312 (Investigational New Drug Application)
- FDA Guidance: Parkinson's Disease: Developing Drugs for Treatment (2023)
- ICH E6(R2): Good Clinical Practice
- ICH E9: Statistical Principles for Clinical Trials
Generated using Clinical Protocol Generation skill
Sources: ClinicalTrials.gov (12 comparable studies), FDA guidance documents
Ready for review with biostatisticians and regulatory affairs
Clinical trial protocols
Draft clinical protocols with built-in regulatory cross-referencing. Claude researches FDA guidances, analyzes comparable trials on ClinicalTrials.gov, and generates structured protocol drafts ready for review with biostatisticians and regulatory affairs.
Clinical Safety Summary
Module 2.7.4 | IND-2024-0892
Study Overview
Drug: ABX-4721 (anti-inflammatory biologic)
Phase: Phase 1
Subjects: 48 healthy volunteers
Duration: 12-week duration
Adverse Event Summary
Total subjects with AEs: 23 (47.9%)
Serious adverse events: 2 (4.2%)
Discontinuations due to AEs: 1 (2.1%)
Deaths: 0
Safety Signals for Phase 2 Monitoring
⚠ Hepatic
Elevated ALT (>3x ULN): 3 subjects (6.3%)
All resolved without intervention within 14 days
→ Recommend: LFT monitoring at weeks 2, 4, 8
⚠ Injection site reactions
Mild erythema: 8 subjects (16.7%)
No treatment required
→ Recommend: Document severity grading in Phase 2
Regulatory References
- 21 CFR 312.32 (IND Safety Reporting)
- ICH E2A: Clinical Safety Data Management
- FDA Guidance: Premarketing Risk Assessment
Generated from uploaded AE reports and lab data
All source documents linked for audit trail
Regulatory affairs
Compile structured submissions from clinical and preclinical data with automatic cross-referencing against FDA guidance. Claude flags gaps in your regulatory package before anything ships.
I'll modernize the pharmacokinetic module. Let me start by understanding the existing FORTRAN code.
Reading the source file...
* pk_compartment.f (847 lines, FORTRAN 77)
* Three-compartment model with IMSL numerical routines
* Last modified 1998
Mapping the dependencies...
* 14 IMSL calls (DIVPRK, LSARG, DGEAR)
* Common blocks for parameter sharing
* Hardcoded clearance constants in the rate equations
Translating the ODE solver to scipy.integrate.solve_ivp and replacing the IMSL routines with NumPy and SciPy equivalents...
Adding type hints, docstrings, and a PKParameters dataclass to replace the common blocks...
Generating pytest cases against the legacy outputs. Validating numerical parity within 1e-6 tolerance...
Modernization complete.
* 23 / 23 tests passing
* Numerical drift below 1e-7
* Reduced from 847 to 312 lines
Legacy code modernization
Build life sciences software faster with Claude Code. Claude helps engineers navigate legacy scientific codebases, write robust code for GxP-regulated environments, and catch compliance issues in PR reviews before they ship.
Claude for Microsoft 365
Refine a clinical study in Word, update trial data in Excel, build research presentations in PowerPoint, and do team coordination in Outlook. Claude carries context across it all.
Claude Cowork
Automate routine lab workflows and data processing tasks. Cowork handles repetitive work like data entry and file management so scientists can focus on discovery.
Claude Code
Accelerate bioinformatics pipelines and validate scientific software under GxP requirements. Turn computational biology challenges into working code in minutes.
Claude connects to your research ecosystem
Literature, lab notebooks, and analysis platforms, all working together in one place.
Pro
For everyday productivity
- Life sciences connectors and skills
- Access to file creation (docs, slides, spreadsheets, and PDFs)
- Access to research
- Access to Claude Code
- Life sciences guides and docs
Max
Get the most out of Claude
Everything in Pro, plus:
- Choose 5x or 20x more usage than Pro*
- Higher output limits for all tasks
- Early access to advanced Claude features
Team
For collaboration across organizations
- Life sciences connectors and skills
- Access to file creation (docs, slides, spreadsheets, and PDFs)
- Single sign-on (SSO)
- Central billing and administration
- Includes Claude Code
- Life sciences guides and docs
Enterprise
For businesses operating at scale
Everything in Team, plus:
- More usage*
- HIPAA-ready infrastructure (added cost)
- Enhanced context window
- Compliance API for observability and monitoring
- Single sign-on (SSO) and domain capture
- Custom data retention controls
Usage limits apply. Prices shown don’t include applicable tax. Price and plans are subject to change at Anthropic's discretion.
Our new blog on AI for science, featuring Anthropic research and practical workflows for scientists
Anthropic partners with the Allen Institute and Howard Hughes Medical Institute to accelerate scientific discovery
AI in life sciences with Dario Amodei, CEO Anthropic, and Diogo Rau, CIDO Eli Lilly
Evaluating Claude’s bioinformatics research capabilities with BioMysteryBench